Kino H, Hama J, Takenaka T, Sugimura K, Kamoi K, Shimada S, Yamamoto Y, Nagata S, Horiuchi M, Katori R
First Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan.
Blood Press Suppl. 1994;5:43-8.
Arterial injury by a balloon catheter produces marked smooth muscle cell proliferation and the participation of angiotensin II in this response has been suggested. In this study, we examined the effect of a novel angiotensin II type I receptor antagonist, TCV-116, on neointimal formation after rat carotid artery balloon injury. Oral administration of TCV-116 at doses of 1, 5 or 10 mg/kg/day significantly reduced the cross-sectional intimal area by 30%, 46% and 54%, respectively, and reduced the ratio of the intimal to medial cross-sectional areas by 23%, 41% and 50%. An angiotensin-converting enzyme inhibitor, lisinopril, had an effect similar to that of TCV-116. The effect of both drugs was significantly correlated with the reduction of both blood pressure and cardiac hypertrophy. We conclude that TCV-116 can prevent neointimal formation after balloon injury as well as reducing blood pressure and preventing cardiac hypertrophy.
球囊导管造成的动脉损伤会引发显著的平滑肌细胞增殖，并且有研究表明血管紧张素II参与了这一反应。在本研究中，我们检测了新型血管紧张素II 1型受体拮抗剂TCV-116对大鼠颈动脉球囊损伤后新生内膜形成的影响。以1、5或10 mg/kg/天的剂量口服TCV-116，可使内膜横截面积分别显著减少30%、46%和54%，并使内膜与中膜横截面积之比分别降低23%、41%和50%。血管紧张素转换酶抑制剂赖诺普利具有与TCV-116相似的作用。两种药物的作用均与血压降低和心脏肥大减轻显著相关。我们得出结论，TCV-116可以预防球囊损伤后新生内膜的形成，同时降低血压并预防心脏肥大。
